Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
|Articles|August 26, 2022
Daily OTC Pearl: Wellblends Immune & Respiratory
Author(s)Saro Arakelians, PharmD
Wellblends Immune & Respiratory is a 3-in-1 blend designed with ingredients to provide advanced immune support.
Advertisement
OTC/Lifestyle Pearl of the Day: Wellblends Immune & Respiratory
Indication: Wellblends Immune & Respiratory is a3-in-1 blend designed with ingredients to provide advanced immune support.
Insight:
- EpiCor is a postbiotic that supports nasal health, respiratory wellness, and a healthy immune response
- Vitamin C is an antioxidant that helps support the immune system by neutralizing free radicals in the body.
- Vitamin D3 helps support a healthy immune response.
- Directions: Adults take 2 capsules daily with water.
- Keep away from children.
- Take away from all other medications.
Source:
Advertisement
Related to this article
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
3
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
4
FDA Grants Accelerated Approval to Ravulizumab for Proteinuria Reduction in IgA Nephropathy
5